Femasys Announces Third Quarter Financial Results for 2025
Femasys Inc. (FEMY)
Company Research
Source: GlobeNewswire
– FDA Approval to Advance Final FemBloc® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non-surgical permanent birth control more accessible and cost-effective to women worldwide, announced its financial results for the third quarter of 2025. Corporate Highlights from 3Q 2025 Announced second partner order for FemBloc in EuropeAnnounced FDA IDE approval to continue enrollment in final phase of the FINALE pivotal trial for FemBlocAnnounced a definitive agreement for the issuance of $12 million in secured convertible notes and accompanying warrants for total potential funding of $58 million, if all warrants are exercised for cashAnnounced the initiation of post-market surveillance study for FemBloc in EuropeAnnounced partnership with Kebomed, a leading Eur
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys (NASDAQ:FEMY) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FEMY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Femasys (NASDAQ:FEMY) is now covered by analysts at Laidlaw. They set a "buy" rating and a $6.50 price target on the stock.MarketBeat
- Femasys GAAP EPS of -$0.10, revenue of $729M [Seeking Alpha]Seeking Alpha
- Femasys Announces Third Quarter Financial Results for 2025 [Yahoo! Finance]Yahoo! Finance
- Femasys Advances Global Growth with Second Partner Order for FemBloc® in Europe [Yahoo! Finance]Yahoo! Finance
FEMY
Sec Filings
- 12/4/25 - Form S-3/A
- 11/19/25 - Form 4
- 11/14/25 - Form 10-Q
- FEMY's page on the SEC website